Cumulative incidence of relapse in patients with B-lineage ALL defined by less than 0.01% MRD at the end of remission induction therapy according to MRD level, presenting features, or study protocol
| Factor . | No. of patients . | 5-year cumulative incidence of relapse, mean ± SE . | P* . |
|---|---|---|---|
| MRD on day 46 | |||
| Less than 0.001% or undetectable | 316 | 5.0 ± 1.5 | .047 |
| 0.001% to less than 0.01% | 63 | 12.7 ± 5.1 | |
| Age at diagnosis | |||
| Less than 1 y | 2 | 0 | .525 |
| 1 to 9 y | 309 | 6.0 ± 1.6 | |
| 10 y or more | 68 | 7.8 ± 3.9 | |
| Race | |||
| White | 301 | 5.7 ± 1.6 | .123 |
| Black | 55 | 12.3 ± 5.3 | |
| Other | 23 | 0 | |
| Sex | |||
| Male | 186 | 7.6 ± 2.2 | .325 |
| Female | 193 | 4.9 ± 2.0 | |
| WBCs, ×109/L | |||
| Less than 50 | 307 | 5.3 ± 1.6 | .106 |
| 50 or more | 72 | 10.6 ± 4.2 | |
| CNS status | |||
| CNS-2 or -3 | 105 | 3.8 ± 2.2 | .289 |
| CNS-1 | 274 | 7.2 ± 1.9 | |
| DNA index | |||
| 1.16 or more | 112 | 7.5 ± 3.3 | .998 |
| Other | 267 | 5.8 ± 1.7 | |
| t(9;22) or BCR-ABL1 | |||
| Absent | 374 | 5.9 ± 1.5 | .073 |
| Present | 5 | 50.0 ± 50.0 | |
| ETV6-RUNX1 | |||
| Absent | 258 | 7.5 ± 2.0 | .098 |
| Present | 105 | 2.9 ± 2.0 | |
| t(4;11) or MLL-AFF1 | |||
| Absent | 378 | 6.3 ± 1.5 | .796 |
| Present | 1 | 0 | |
| t(1;19) or TCF3-PBX1 | |||
| Absent | 351 | 5.7 ± 1.5 | .095 |
| Present | 28 | 13.5 ± 7.5 | |
| IKZF1 deletions | |||
| No | 202 | 7.7 ± 2.4 | .620 |
| Yes | 13 | 11.1 ± 11.1 | |
| NCI risk criteria | |||
| Standard | 251 | 5.2 ± 1.7 | .122 |
| High | 126 | 8.6 ± 3.0 | |
| Study protocol | |||
| Total 13A | 13 | 0 | .541 |
| Total 13B | 48 | 10.4 ± 4.5 | |
| Total 14 | 25 | 0 | |
| Total 15 | 293 | 6.5 ± 1.9 |
| Factor . | No. of patients . | 5-year cumulative incidence of relapse, mean ± SE . | P* . |
|---|---|---|---|
| MRD on day 46 | |||
| Less than 0.001% or undetectable | 316 | 5.0 ± 1.5 | .047 |
| 0.001% to less than 0.01% | 63 | 12.7 ± 5.1 | |
| Age at diagnosis | |||
| Less than 1 y | 2 | 0 | .525 |
| 1 to 9 y | 309 | 6.0 ± 1.6 | |
| 10 y or more | 68 | 7.8 ± 3.9 | |
| Race | |||
| White | 301 | 5.7 ± 1.6 | .123 |
| Black | 55 | 12.3 ± 5.3 | |
| Other | 23 | 0 | |
| Sex | |||
| Male | 186 | 7.6 ± 2.2 | .325 |
| Female | 193 | 4.9 ± 2.0 | |
| WBCs, ×109/L | |||
| Less than 50 | 307 | 5.3 ± 1.6 | .106 |
| 50 or more | 72 | 10.6 ± 4.2 | |
| CNS status | |||
| CNS-2 or -3 | 105 | 3.8 ± 2.2 | .289 |
| CNS-1 | 274 | 7.2 ± 1.9 | |
| DNA index | |||
| 1.16 or more | 112 | 7.5 ± 3.3 | .998 |
| Other | 267 | 5.8 ± 1.7 | |
| t(9;22) or BCR-ABL1 | |||
| Absent | 374 | 5.9 ± 1.5 | .073 |
| Present | 5 | 50.0 ± 50.0 | |
| ETV6-RUNX1 | |||
| Absent | 258 | 7.5 ± 2.0 | .098 |
| Present | 105 | 2.9 ± 2.0 | |
| t(4;11) or MLL-AFF1 | |||
| Absent | 378 | 6.3 ± 1.5 | .796 |
| Present | 1 | 0 | |
| t(1;19) or TCF3-PBX1 | |||
| Absent | 351 | 5.7 ± 1.5 | .095 |
| Present | 28 | 13.5 ± 7.5 | |
| IKZF1 deletions | |||
| No | 202 | 7.7 ± 2.4 | .620 |
| Yes | 13 | 11.1 ± 11.1 | |
| NCI risk criteria | |||
| Standard | 251 | 5.2 ± 1.7 | .122 |
| High | 126 | 8.6 ± 3.0 | |
| Study protocol | |||
| Total 13A | 13 | 0 | .541 |
| Total 13B | 48 | 10.4 ± 4.5 | |
| Total 14 | 25 | 0 | |
| Total 15 | 293 | 6.5 ± 1.9 |
All indicates acute lymphoblastic leukemia; MRD, minimal residual disease; WBC, white blood cell; CNS, central nervous system; and NCI, National Cancer Institute.
Gray test.